Synthetic lethality and synergetic effect: the effective strategies for therapy of IDH-mutated cancers
Open Access
- 23 August 2021
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 40 (1) , 1-12
Abstract
Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) gain a novel function for the conversion of α-ketoglutarate (α-KG) to oncometabolite R-2-hydroxyglutarate (R-2-HG). Two molecular entities namely enasidenib (AG-221) and ivosidenib (AG-120) targeting mIDH2 and mIDH1 respectively, have already been approved by FDA for the treatment of relapsed/refractory acute myeloid leukemia (R/R AML). However, the low responses, drug-related adverse effects, and most significantly, the clinically-acquired resistance of AG-221 and AG-120 has shown great influence on their clinical application. Therefore, searching for novel therapeutic strategies to enhance tumor sensitivity, reduce drug-related side effects, and overcome drug resistance have opened a new research field for defeating IDH-mutated cancers. As the effective methods, synthetic lethal interactions and synergetic therapies are extensively investigated in recent years for the cure of different cancers. In this review, the molecules displaying synergetic effects with mIDH1/2 inhibitors, as well as the targets showing relevant synthetic lethal interactions with mIDH1/2 are described emphatically. On these foundations, we discuss the opportunities and challenges for translating these strategies into clinic to combat the defects of existing IDH inhibitors.Keywords
Funding Information
- Natural Science Foundation of Suzhou (SYSD2017154)
- Fund for development of Science and Technology of Nanjing Medical University (NMUB2020295, NMUB2020295)
This publication has 123 references indexed in Scilit:
- K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomasActa Neuropathologica, 2012
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumphTrends in Pharmacological Sciences, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular MetabolismJNCI: Journal of the National Cancer Institute, 2010
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1Science, 2009
- Chromatin Modifications and Their FunctionCell, 2007
- Role of Histone H3 Lysine 27 Methylation in Polycomb-Group SilencingScience, 2002